Lymphomas of Waldeyer’s ring by Mrówka-Kata, Katarzyna et al.
142 www.fmr.viamedica.pl
WYBRANE
PROBLEMY
KLINICZNE
Copyright © 2014 Via Medica 
ISSN 1897–3590
Chłoniaki pierścienia chłonnego 
Waldeyera
Lymphomas of Waldeyer’s ring
ABSTRACT
The problem of Waldeyer’s ring lymphomas was presented in this paper. The pathogenesis, 
clinical manifestation, diagnostic procedures were presented in details. Currant treatment 
strategies included bone marrow and stem cells transplantation were discussed. Selected 
kinds of lymphomas either non-Hodgkin and Hodgkin, involving Waldeyer’s ring elements 
were widely presented. 
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STRESZCZENIE
W artykule przedstawiono problem chłoniaków pierścienia Waldeyera. W szczególności omó-
wiono patogenezę, objawy kliniczne i diagnostykę. Współczesne leczenie obejmujące trans-
plantację szpiku i komórek pnia jest dyskusyjne. W pracy zostały przedstawione wybrane przy-
kłady chłoniaków typu non-Hodgkin i Hodgkin obejmujące elementy pierścienia Waldeyera.
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INTRODUCTION 
The term Waldeyer’s ring (WR) is used to 
encompass the lymphoid tissues of the fau­
cial tonsils, nasopharynx, base of tongue, and 
oropharynx and, as defined by others, is an 
extranodal but not an extralymphatic site. 
Waldeyer’s ring may be involved by a varie­
ty of neoplasms, and carcinomas most often 
metastatic from nearby head and neck sites. 
Lymphomas are a heterogeneous group of 
lymphoproliferative malignancies, originating 
from lymphocytes or their derivates, with dif­
fering patterns of behavior and responses to 
treatment. Lymphomas usually originates in the 
lymphoid tissues and can spread to other organs. 
The current World Health Organization 
(WHO) classification divides lymphoid malig­
nancies largely into T­cell and B­cell neoplasm 
(both constituting non­Hodgkin lymphoma, 
NHL), and Hodgkin’s disease. The division of 
lymphomas according WHO 2008 classifica­
tion is presented below. 
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PATHOGENESIS OF LYMPHOMAS
Malignances affecting B cell lineage com­
prise the vast majority of human lympho­
mas. There are at least 15 different types of 
B cell lymphomas (BCLs), differing in clinical 
behavior, biological phenotype, pathogene­
sis, and response to treatment. Irrespective 
of their type, however, most BCLs share two 
features: chromosomal translocations that 
involve an immunoglobuline gene and one 
or another proto­oncogene, and expression 
of a B cell antigen receptor (BCR) [1]. Chro­
mosomal translocation have long been con­
sidered crucial to the pathogenesis of the tu­
mors. The human BCL6 gene on chromosome 
3 band q27, which encodes a transcriptional 
repressor, is implicated in the pathogenesis 
of human lymphomas, especially the diffuse 
large B­cell type (DLBCL) [2, 3]. BCL­6 is 
a transcriptional repressor that is required 
for mature B cells to differentiate into germi­
nal center B cells during an immune respon­
se. Normal germinal center B cells express 
BCL­6 at high levels but BCL­6 expression 
is silenced during plasmatic differentiation. 
BCL­6 is deregulated by chromosomal trans­
locations in roughly 20% of DLBCLs, but the 
high expression of BCL­6 in DLBCLs is not 
accounted for by these translocations. Rather, 
BCL­6 is expressed in DLBCLs along with 
a host of other germinal center B cell restric­
ted­genes because these DLBCLs are deri­
ved from normal germinal germinal center 
B cells and retain much of their biology [4]. 
In keeping with these notions, DLBCLs have 
ongoing somatic hypermutation of their im­
munoglobulin genes, a characteristic feature 
of normal germinal center B cells. To elucida­
te the mechanism by which BCL­6 regulates 
germinal center B cell differentiation, gene 
expression profiling was used to identify the 
target genes of BCL­6 expression. One gro­
up of BCL­6 target genes are genes that are 
induced when B cells are activated through 
the antigen receptor, including cyclin D2, 
CD69, CD44, and MIP­1 alfa [5]. By bloc­
king expression of B cell activation genes, 
BCL­6 may guide an antigen­stimulated B 
cell towards germinal center differentiation 
and away from the alternate fate of rapid pla­
smacytic differentiation. Another important 
BCL­6 target gene is p27kip1, which encodes 
a negative regulator of cell cycle progression. 
By repressing p27kip1, BCL­6 may contribute 
to the extraordinarily high proliferation rate 
of germinal center B cells [6, 7]. Particularly 
illuminating BCL­6 target gene is Blimp­1, 
which encodes a transcriptional repressor 
that is required for plasma cell differentia­
tion. BCL­6 binds to a motif in intron 5 of 
the Blimp­1 gene that is conserved between 
the human and mouse genes. Since BCL­6 is 
bound to the site in vivo, as judged by chro­
matin immunoprecipitation, Blimp­1 appe­
ars to be a direct target of BCL­6 repression. 
Presently, are also increasing evidence that 
signaling from BCR may be a coconspirator 
in lymphomas pathogenesis [8]. 
RISK FACTORS OF LYMPHOMAS DEVELOPING
Numerous risk factors may be responsible 
for DNA damage within the body’s lympho­
cytes. One of them, such as age and genetics, 
are non­modifiable (beyond our control). 
Other factors, such as environmental or li­
festyle­related variables are modifiable (can 
be changed).
The risk factors now believed to have 
strongest associations with lymphoma inclu­
de the following:
 — the rate of NHL increase exponentially 
with age between 20 and 79 years. The rate 
of HL is highest in two age groups: young 
adults (aged 15–40) and older adults (age 
55 and more);
 — sex: in generally, both HL and NHL affect 
men more often than woman [9];
 — infections: the risk for developing NHL is 
increased in people who have been expo­
sed to:
•	human T­lymphotropic virus type 
I (HTLV­1),
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•	Epstein­Barr (EBV) virus,
•	human immunodeficiency virus (HIV),
•	human herpes virus,
•	malaria, especially in areas of Africa, 
where Burkitt’s lymphoma is common,
•	Helicobacter pylori, this bacterial infec­
tion can cause lymphomas of the sto­
mach;
 — medical conditions:
•	autoimmune diseases (e.g. rheumatoid 
arthritis, systemic lupus erythematosus, 
Sjogren’s syndrome), 
•	inherited immune deficiency syndromes 
(e.g. ataxia teleangiectasia),
•	organ transplants that require the use 
of immunosuppressant drugs;
 — chemicals: exposure to chemicals also 
increase the risk for NHL. They include 
the following:
•	benzene and certain other solvents, 
•	herbicides,
•	pesticides,
•	medications — e.g. antiepileptic medi­
cine — phenytoin;
 — genetics: rates of lymphoma and leukemia 
(e.g. chronic lymphocytic leukemia, CLL) 
are especially high in some Jewish popu­
lation, whereas Asian population rarely 
develop CLL [10]. 
Cancer therapy
Patients who have received chemotherapy 
and/or radiotherapy for previous cancers 
have an increased risk for developing NHL 
or secondary leukemia [10, 11]. 
On the other hand, allergic and atopic 
conditions and their correlates such as early 
birth order, appear to be associated with a de­
creased risk of NHL developing [12]. 
CLINICAL MANIFESTATION
Malignant lymphoma is primarily a disorder 
of the lymph nodes; however they may arise 
from extranodal sites, and there appears to 
be an increasing incidence of such lympho­
mas during the past few decades. Extranodal 
presentation concern 24% to 48% of all non­
­Hodgkin lymphomas (NHL), constituting 
the second most frequent type of extranodal 
malignant lymphomas. Approximately 10% 
of patients with NHL present extranodal di­
sease in the head and neck region [13]. Fur­
thermore, more than half of these head and 
neck lymphomas occur in the Waldeyer’s ring, 
and 40% to 50% of these arise from the ton­
sil. In published studies, approximately 90% 
of all lymphomas involving WR are types of 
NHL. In 3–10% of patients with non­Hodg­
kin’s lymphoma involvement of WR (prima­
ry or secondary in patient with disseminated 
disease) is found. Characteristically, these 
lymphomas arise in elderly men in the age 
group 50–60 years, and present as a tonsillar 
swelling, cervical adenopathy, dysphagia, ody­
nophagia, or with a sore throat [14]. 
All varieties of non­Hodgkin’s lympho­
mas are seen in WR, but up to 85% of such 
lymphomas are diffuse, and most diffuse lym­
phomas are of the B­cell origin and the most 
common histological type is DLBCL accor­
ding to the WHO classifications. As far as 
other types of NHLs, extranodal natural kil­
ler/T­cell lymphoma of nasal type and a lesser 
number of other types, including extranodal 
marginal zone B­cell lymphoma of mucosa­
­associated lymphoid tissue, mantle cell lym­
phoma, and peripheral T­cell lymphoma are 
observed [15].
Diagnostics of Waldeyer’s ring lymphoma
In the past 10 years, fene needle aspiration 
(FNA) cytology has become accepted as 
a means diagnosis and typing common forms 
of lymphoma, particularly small lymphocytic 
lymphoma, follicular lymphoma, and large B 
cell lymphoma [16]. The usefulness of FNA 
cytology in the diagnosis of these lymphomas 
is reliant on immunoflow cytometry (IFC) and 
cell block imunohistochemistry (IHC). It is 
also reliant on the pathologist making “near 
patient” provisional assessment of the nature 
of the specimen and then collecting appropria­
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stead expresses genes that are induced during 
mitogenic stimulation of blood B cells. These 
two subgroups of DLBCL differ in the expres­
sion of thousands genes, and in this respect 
they are as different as acute myelogenous 
leukemia and acute lymphoblastic leukemia. 
More recently, a third subgroup of DLBCL 
has been defined by gene expression profiling, 
termed primary mediastinal B cell lympho­
ma (PMBL). These three DLBCL subgroups 
should be considered separate disease enti­
ties since they arise from B cells at different 
stages of differentiation, utilize different on­
cogenic pathways, and have distinct clinical 
behavior [21]. These DLBCL subgroups also 
differ in their care rate following anthracycli­
ne­based multiagent chemotherapy. Patients 
with ABC DLBC, GCB DLBC and PMBL 
have five­year survival rates of 31%, 59% and 
64% respectively. Relatively few relapses oc­
cur beyond five years, so these survival rates 
roughly reflect the probability that patients in 
each DLBCL subgroup will be cured by che­
motherapy [22]. 
Peripheral T/NK (natural killer)-cell 
lymphomas
As a rule, these are also rare in Waldeyer’s 
ring. Only 4 (6%) of the 65 cases from SGH, 
TTSH and CGH seen from 1992 to 1996 were 
of T­cell phenotype. Separate data accumu­
lated from 1991 to 1999 came from NUH. Of 
26 Waldeyer’s ring lymphomas, only 5 (19%) 
were of T­cell phenotype, resulting in B:T­cell 
lymphoma ratio of 4.2. 
Although NHLs of the Waldeyer’s ring 
are mainly of the diffuse large B­cell type, 
WR is the most common site of nasal­type 
NK/T­cell lymphoma in the upper aerodige­
stive tract [22]. 
For the WR­NKTL cases, the nasopharynx 
(57%) is the most frequently involved, followed 
by the tonsil (38%). In contrast, in all patients 
with NHL of Waldeyer’s ring, the tonsil was the 
most frequently involved site, accounting for 
50% to 80% of all primary lesions [23].
te specimens. Standard panels of lymphomas 
characteristic antibodies are evolved with the 
acquisition of a flow cytometer [17]. In some 
cases, more specialized panel to investigate 
a specific diagnosis. The number of used is 
sometimes restricted by the scarcity of cells. 
For some cases cell blocks for immunohi­
stochemistry are collected, usually when FNA 
is not diagnostic, showing overtly malignant 
cytology [18]. In the cases of B­cell lymphomas, 
B­cell markers CD 19+, CD 20+ are assessed 
and proportion light and heavy chains anti­
­kappa and anti­lambda, showing light chain 
restriction. In the cases of Burkitt lymphoma, 
Burkitt­like B cell lymphoma CD 10 and CD 77, 
showing 8q24c­myc breakpoint gene rearran­
gement are strongly expressed [18]. A “small 
cell” lymphoma with an immunophenotype of 
CD5+, CD 19+, and CD23 — strongly sugge­
sts a mantle cell lymphoma.
HIGH-GRADE B-CELL LYMPHOMAS
Diffuse large B-cell lymphoma
These are lymphomas composed of pattern 
less sheets of large, transformed lymphoid 
cells with variable cytoplasmic content and 
enlarged, vesicular nuclei containing disper­
sed (activated) chromatin that allows one­to­
­several nucleoli to become visible in each 
nucleus [19]. This turns out to be the largest 
group of lymphomas involving Waldeyer’s 
ring, quoted figures in large series being: 57% 
“centroblastic” (i.e. morphologically resem­
bling the B­blasts of the germinal centre) of 
79 cases, 66% of 77 cases and 75% of 65 cases 
(SGH/TTSH/CGH, 1992–1996) [20].
Gene expression profiling studies reve­
led that that DLBCL is comprised of at le­
ast two molecularly and clinically distinct 
diseases. One subgroup of DLBCL, termed 
germinal center B cell­like (GCB) DLBCL, 
expresses genes that are hallmarks of normal 
germinal center B cells. By contrast, another 
DLBCL subgroup, termed activated B­cell­
­like (ABC) DLBCL, lacks expression of ger­
minal center B cell­restricted genes and in­
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Extranodal NK/T­cell lymphoma, nasal 
type, recently was recognized as a distinct 
entity of malignant lymphoma. Because this 
type of lymphoma often shows an angiocentric 
and angiodestructive growth pattern, together 
with a broad cytologic spectrum of atypical 
cells and a zonal necrosis, it was categorized 
as angiocentric lymphoma in the revised Eu­
ropean­American lymphoma classification. 
These lymphomas are uncommon in the U.S. 
and Europe, but they are prevalent in East 
Asia and in certain parts of Central and South 
America [22]. 
Patients with WR­NKTL showed better 
response to radiotherapy than chemotherapy. 
Recently, radiotherapy as primary treatment 
for early­stage nasal NK/T­cell lymphoma has 
been validated in many large retrospective 
studies. Primary radiotherapy results in a bet­
ter outcome compared with chemotherapy 
alone or initial chemotherapy, and the addi­
tion of chemotherapy to radiotherapy does 
not further improve survival rates for stage 
I and II diseases [21].
Extranodal marginal zone lymphoma of 
MALT
MALT lymphomas were first by Issacson and 
Wright in 1983 in a small series of patients 
with low grade B cell gastrointestinal lympho­
mas. Although MALT lymphomas — extrano­
dal lymphomas arising from MALT — occur 
most frequently in the stomach, they have 
also been described at various non­gastroin­
testinal sites. In Waldeyer’s ring, these lym­
phomas constitute only a minority of cases, 
the percentages derived from various large 
series being 3.6% of 329 cases, 1.3% of 79 ca­
ses and 0% of 65 cases (SGH/TTSH/CGH, 
1992–1996) [22]. MALT lymphomas are cha­
racterized by neoplastic marginal cells which 
display a variable combination of coloniza­
tion of reactive germinal centers, plasma 
differentiation, and destructive epithelial 
infiltration forming lymphoepithelial lesions 
[24]. Immunohistochemical examination 
often shows the characteristic B cell lympho­
ma with monoclonal expansion by monotypic 
cytoplasmic immunoglobulin. This low­grade 
malignancy has a tendency to remain localized 
to the primary site and to respond favorably 
to local treatment such as surgery and/or ra­
diotherapy. The outcome and prognosis for 
MALT lymphomas are more favorable than 
for other extranodal lymphomas reported in 
the literature [23].
Mantle cell lymphoma
Mantle cell lymphoma (MCL) is a non­Hod­
gin’s lymphoma which has a marked male pre­
dominance that typically is nodal­based but 
can involve extranodal sites. Among the more 
common extranodal sites of involvement are 
the tonsils, large intestine, stomach, upper 
aero digestive tract. This again, is rare enti­
ty in Waldeyer’s ring, quotable percentages 
being: 11% “centrocytic” of 79 cases, 4% of 
77 cases and 3% of 65 cases (SGH/TTSH/CGH 
1992–1996) [24].
Typically, mantle cell lymphoma has ra­
ther characteristic nuclear features, including 
monotonous nuclei with finely stippled chro­
matin. However, there are variants with an 
atypical appearance and immunophenotype. 
To make a definite diagnosis one usually ne­
eds to demonstrate nuclear overexpression of 
cyclin D1 on immunohistochemistry. 
One of the outcomes of the recent change 
in lymphoma classification is that mantle cell 
lymphoma under the current WHO classifica­
tion has been found to correspond largely to 
what used to be called “centrocytic lympho­
ma” in the preceding Kiel classification [23].
Low-grade follicular lymphoma
Follicular lymphoma (FL) is a prototype of 
indolent lymphoma, a slowly growing lympho­
ma arising from follicular center B cells with 
a scarce tendency to invade to non­lymphoid 
tissues and a protracted clinical course. In 
physiological conditions, the stable formation 
of germinal centers requires the presence of 
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functionally specialized T cells, dendritic and 
stromal cell subpopulations. FL is recogni­
zed as a disease of functional B cells in which 
T­cell co stimulation is essential for the ma­
intenance and ongoing development of B­cell 
secondary follicles. 15% of patients with FL 
have objective tumor regression in the absen­
ce of any antitumoral therapy. On the other 
hand, tumor transformation and development 
of unresponsiveness to standard chemothera­
py or immunochemotherapy regimens in the 
course of FL represent the main causes of de­
ath in patients with this lymphoma. Follicular 
lymphomas occur commonly in the lymph no­
des, and duodenum. FL is reported to be rare. 
Quoted figures for the frequency of follicular 
lymphoma in Waldeyer’s ring lymphoma series 
are: 6% of 79 cases 6% of 77 cases and 9% of 
65 cases (SGH/TTSH/CGH, 1992–1996) [25].
Burkitt’s lymphoma
Burkitt’s lymphoma, an aggressive form of 
non­Hodgkin’s B­cell lymphoma is usually 
diagnosed in children and young adults, and 
to a lesser extend in middle­aged adults. En­
demic, sporadic (non­endemic) and immu­
nodeficient variants have been recognized. 
They are recognized as small non­cleaved 
cell lymphomas displaying a starry sky appe­
arance due to the high rate of proliferation 
and spontaneous cell death. Chromosomal 
translocation involving the Myc oncogene are 
to believed to highlight the hallmark of the 
disease [26]. Endemic variant is found in equ­
atorial Africa, as associated with Epstein­Barr 
virus (EBV) infection, as well as frequent 
concomitant malaria infection. The sporadic 
form tends to present in the lymphoid tissues 
of the gut, often presenting as masses in the 
Waldeyer’s ring or terminal ileum, or even 
massive abdominal involvement. This form of 
Burkitt’s lymphoma involve WR in 3% to 5% 
of cases. Bone marrow involvement is com­
monly seen in progressive disease.
EBV involvement is reported in around 
15–30% of cases. The immunodeficient form 
is often associated with HIV infection, and 
may also be seen in post­transplant patients 
who are chronically immunosuppressed [25].
However, it is important to recognize as an 
oncologic emergency, being a highly aggressi­
ve lymphoma characterized primarily by ac­
tivation of the c­myc oncogene that drives its 
cell proliferation fraction to virtually 100%, 
thereby rendering it also highly chemosensi­
tive and prone to the tumor lysis syndrome.
Hodgkin lymphoma
Hodgkin lymphoma (HL) represents approxi­
mately 4% of all lymphomas of the head and 
neck, and most of these neoplasms involve 
lymph nodes, most frequently in the cervical 
regions. Extranodal involvement by HL, in­
cluding Waldeyer’s ring, is rare. Among this 
group, HL involving Waldeyer’s ring, which 
encompasses the lymphoid tissues of the ton­
sils, nasopharynx, base of the tongue, and oro­
pharynx wall, is even more rare. For example, 
Todd and Michaels reported a frequency of 
1% for involvement of the nasopharynx and 
1.5% for tonsil and oropharynx [26]. 
Similarly, Kaplan and colleagues reported 
that 5 (1.8%) of 285 consecutive patients with 
HL had involvement of Waldeyer’s ring. As 
a result, most previously published series of 
HL involving Waldeyer’s ring have been small 
groups of patients or case reports.
However, the incidence of extranodal HL 
is increasing due to the emergence of the acqu­
ired immunodeficiency syndrome. EBV has 
been implicated in the etiopathogenesis of HL 
and EBV­LPM has transforming and oncoge­
nic properties. Both HL and Infectious Mo­
nonucleosis are EBV­related and likely to be 
endpoints of distinct pathogenic pathway [26].
TREATMENT MANAGEMENT
The treatment in the individual lymphoma 
subtypes is largely dictated by the previous 
broad categorization into low­ and high­grade 
lymphomas, as well as the sites of involve­
ment. At the end of the scale, patients pre­
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senting with low­grade lymphomas who are 
asymptomatic may simply be followed without 
treatment until symptoms develop or trans­
formation occurs [27]. 
At the other end of the scale, patients 
presenting with high­grade disease may be 
successfully treated with multi­agent chemo­
therapy with most attaining a remission and 
up to 50% of patients achieving long­term 
disease­free survival. Generally, treatment 
polices for Waldeyer’s ring lymphomas have 
included RT with or without CTh for limited 
stage disease and aggressive CTh with or wi­
thout RT for advanced stage disease [26]. The 
general guidelines recommend radiotherapy 
for localized lymphomas, cyclophosphamide, 
vincristin and prednisone chemotherapy or 
chlorambucil for stage III–IV indolent NHL, 
cyclophosphamide, hydroxydaunomycin, vin­
cristin and prednisone chemotherapy for sta­
ge II–IV aggressive and very aggressive NHL, 
followed by radiotherapy for bulky tumors or 
persistent lesions. Chemotherapy schemes 
were divided into two groups: one with an 
anthracycline and other without (mitoxan­
trone­based chemotherapy was not conside­
red among the anthracyclines). No specific 
recommendations were made for the treat­
ment of patients with WR NHL [26].
Radiotherapy has a role in low­ and inter­
mediate­grade NHL but is usually inappro­
priate for treatment of high­grade lympho­
mas which are frequently widely disseminated 
tumors. Many studies revealed that patients 
receiving an RT dose of > or = 45 Gy had 
statistical significant improvement in CR 
(complete response), DSF (disease­free su­
rvival) and OS (overall survival) rates over 
those treated with a lower doses [27].
In the past decade, overall survival impro­
vements have been observed in the two most 
common lymphoma histologies: diffuse large 
B cell lymphoma and follicular lymphoma. 
The monoclonal antibody rituximab has signi­
ficantly contributed to these improvement the­
rapeutic outcomes. Rituximab is a monoclonal 
antibody targeting the CD20 molecule on B 
lymphocytes. The initial indication was for the 
treatment of patients with relapsed or refrac­
tory, low­grade or follicular, CD20 positive, 
B­cell, non­Hodgkin lymphoma (NHL) [28]. 
Subsequent indications have expanded to 
include first­line treatment of follicular, 
CD20 positive, B­cell NHL in combination 
with cyclophosphamide, vincristine, and 
prednisone (CVP) chemotherapy; treatment 
of low­grade, CD20 positive, B­cell NHL in 
patients with stable disease or who achieved 
a partial or complete response following first­
­line treatment with CVP chemotherapy; and 
for the first line treatment of diffuse large 
B­cell, CD20­positive, NHL in combination 
with cyclophosphamide, doxorubicin, vincri­
stin, and prednisone (CHOP) or other antra­
cycline­based chemotherapy regimens. Sub­
sequent antibodies to reach the market for 
lymphoma chemo­immunotherapy include 
the radiolabeled anti­CD20 antibodies iodi­
ne­131­tositumomab and ibritumomab tiu­
xetan — each indicate for the treatment of 
relapsed or refractory low grade or follicular 
lymphoma, including transformed lymphoma 
and rituximab­refractory lymphoma. Howe­
ver, once relapse occurs, particularly if re­
mission is short, further response to salvage 
chemotherapy is difficult to sustain [28].
Patients who relapse after achieving com­
plete remission (CR) or never achieve CR of 
non­Hodgkin lymphoma can rarely be cured 
with further chemotherapy. However, high­
­dose chemoradiotherapy with autologous 
bone marrow or peripheral blood stem­cell 
transplantation is curative in some patients 
and is superior to conventional chemothera­
py [29]. Chemosensitivity of the lymphoma 
is one of the most important predictors of 
outcome with autologous transplantation. 
Intensification of conditioning regimens has 
not resulted in an increase in disease­free 
survival but is associated with an increase in 
transplantation­related deaths. The success of 
high­dose chemoradiotherapy and stem­cell 
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transplantation for patients with advanced he­
matologic malignancies is limited primarily by 
a high incidence of relapse. The cytoreductive 
regimen used very often consisted of high­
­dose cyclophosphamide, etopside, and total 
body irradiation [29].
Authors have reported 5­year survival 
rates of 60% to 80% for patients with early 
stage disease. Qin et all reported a 5 year OS 
of 84% for stage I–II tonsil NHL, whereas 
Gao et all reported an OS of 65% for these 
patients. Large size of the tumor, poor perfor­
mance status, presence of systemic symptoms 
and a higher Ann Arbor stage were indicative 
of a poor prognosis. 
DIFFERENTAL DIAGNOSIS
Waldeyer’s ring lymphomas should be diffe­
rentiated with other malignances especially 
squamous cell carcinoma, tonsillar hypertro­
phy, tonsillar swelling, sore through, painful 
swallowing accompanied with autoimmunolo­
gical diseases like rheumatoid arthritis, Sjo­
gren syndrome or systemic lupus erythemato­
sus. They should be also considered in patients 
with immunological deficiencies either acqu­
ired (HIV/Aids infection) or congenital syn­
dromes (e.i. ataksia — teleangiectasia) [30]. 
CONCLUSIONS
Lymphomas affecting Waldeyer’s ring should 
be taken under consideration in all cases of 
tonsillar hypertrophy, especially one­sided, 
asymmetric hypertrophy especially in group 
of young adults and adults over 40 years old. 
Clinical symptoms mentioned above should 
also rise suspicious in the direction of lympho­
mas in these groups of patients. 
R E F F E R E N C E S
1. Kojima M., Nakamura S., Shimizu K., Itoh H., Masawa 
N. Marginal Zone B cell lymphomas of Waldeyer’s 
ring. Pathol. Res. Pract. 2001; 197: 781–784.
2. Aguilera N.S., Wenig U.B., Abbondazo S. The blastic 
variant of mantle cell lymphoma arising in Waldeyer’s 
tonsillar ring. The Journal of Laryngology and Otology 
1998; 112: 991–994.
3. Laskar S., Bahl G., Muckaden A., Pai S., Nair R., Gup-
ta S. et all. Non-Hodgkin’s lymphoma of Waldeyer’s 
ring in children: outcome using chemotherapy and 
involved field radiotherapy. Clin. Oncology 2008; 20: 
613–618.
4. Moghie G., Borges A., Soman Ch., Naresh K. Hodgki-
n’s disease involving Waldeyer’s ring: a study of four 
cases. Leukemia and Lymphoma 2001; 41: 151–156.
5. Quinones-Avilla M.P., Gonzalez-Longoria A.A., Admi-
rand J.H., Medeiros J. Hodgkin lymphoma involving 
Waldeyer’s ring: a clinicopathologic study of 22 ca-
ses. Am. J. Clin. Pathol. 2005; 123: 651–656.
6. Tan L.H.C. Lymphomas involving Waldeyer’s ring: ple-
acement, paradigms, peculiarities, pitfalls, patterns 
and postulates. Ann. Acad. Med. Singapore 2004; 
333: 15–26.
7. Li Y.X., Fang H., Liu Q.F., Qi S.N., Wang H., Jin J. et all. 
Clinical features and treatment outcome of nasal-type 
NK/T-cell lymphoma of Waldeyer’s ring. Blood 2008; 
112: 3057–3064.
8. Krol A.D., Le Cessie S., Snijder S., Kluin-Nelemans 
J.C., Kluin Ph.M., Noordijk E.M. Waldeyer’s ring lym-
phomas: a clinical study from the Comprehensive 
Cancer West Population based NHL registry. Leuk. 
and Lymphoma 2001; 42: 1005–1013.
9. Li Y.X., Fang H., Liu Q.F., Lu J., Qi S.N., Wang H., Jin 
J. Clinical features and treatment outcome of nasal-
-type NK/T-cell lymphoma of Waldeyer’s ring. Blood 
2008; 112: 3057–3064.
10. Laskar S., Bahl G., Muckaden M.A., Nair R., Gupta 
S., Bakshi A. Primary diffuse large B-cell lymphoma 
of the tonsil. Cancer 2007; 110: 816–823. 
11. Isobe K., Uno T., Tamaru J., Kawakami H., Ueno N., 
Wakita H. Extranodal natural killer/T-cell lymphoma, 
nasal type. Cancer 2006; 106: 609–615.
12. Zintzaras E., Voulgarelis M., Moutsopoulus H.M. The 
risk of lymphoma development in autoimmune dise-
ases: a meta-analysis. Arch. Intern. Med. 2006; 166: 
1233–1234.
13. Smedby K.E., Hjalgrim H., Askling J., Chang E.T., 
Gregersen H. Autoimmune and chronic inflammatory 
disorders and risk of non-Hodgkin lymphoma by sub-
type. J. Natl. Cancer Inst. 2006; 98: 51–60.
14. Engels E.A. Infectious agents as causes of non-Hodg-
kin lymphoma. Cancer Epidemiol. Biomarkers Prev. 
2007; 16: 401–404. 
15. Grulich A.E., Vajdic C.M. The epidemiology of non-
-Hodgkin lymphoma. Pathology 2005; 37: 409–419.
16. Grulich A.E., Vajdic C.M., Cozen W. Altered immunity 
as a risk factor for non-Hodgkin lymphoma. Cancer 
Epidemiol. Biomarkers Prev. 2007; 16: 405–408.
17. Caporaso N.E., Goldin L.R., Anderson W.F., Landgren 
O. Currant insight on trends, causes, and mechani-
150 www.fmr.viamedica.pl
WYBRANE
PROBLEMY
KLINICZNE
sms of Hodgkin’s lymphoma. Cancer J. 2009; 15: 
117–123.
18. Jarret R.F. Risk factors for Hodgkin’s lymphoma by 
EBV status and significance of detection of EBV geno-
mes in serum of patients with EBV-associated Hodg-
kin’s lymphoma. Leuk. Lymphoma 2003; 44: 27–32.
19. Smedby K.E., Vajdic C., Falster M., Engels E., Mar-
tinez-Maza O., Turner J. Autoimmune disorders and 
risk of non-Hodgkin lymphoma subtypes: a pooled 
analysis within the InterLymph Consortium. Blood 
2008; 118: 4029–4038.
20. Connor C.D. Panel discussion: myeloma and lympho-
ma. Cancer Imaging 2004; 4: 111–135.
21. Baron B.W., Zelenik-Lee N., Baron M., Theisler C., 
Huo D., Krasowski D., Thirman M., Baron R., Baron 
J. Repression of the PDCD2 gene by BCL6 and the 
implications for the pathogenesis of human B and T 
cell lymphomas. Proc. Natl. Acad. Sci. U.S.A. 2007; 
104: 7449–7454. 
22. Staud L., Sandeep D. The biology of human lymphoid 
malignancies revealed by gene expression profiling. 
Adv. Immunol. 2005; 87: 163–208.
23. Thompson J., Fisher R., LeBlanc M., Forman S., 
Press O., Unger J. Total body irradiation, etopside, 
cyclophosphamide, and autologous peripheral blood 
stem-cell transplantation followed by randomization 
to therapy with interleukin-2 versus observation for 
patients with non-Hodgkin lymphoma: results of 
a 3 phase randomized trial by the Southwest Oncolo-
gy Group (SWOG 9438). Blood 2008; 111: 4048–4054.
24. Mayall F., Darlington A., Harrison B. Fine needle aspi-
ration cytology in the diagnosis of uncommon types of 
lymphoma. J. Clin. Pathol. 2003; 56: 821–825.
25. Link B., Friedberg J. Monoclonal antibodies in lymphoma 
— the first decade. Semin. Hematol. 2008; 45: 71–74.
26. Campo E., Chott A., Kinney M.C., Leoncini L., Me-
ijer C.J., Papadimitriou C.S., Piris M.A., Stein H., 
Swerdlow S.H. Update on extranodal lymphomas. 
Conclusions of the workshop held by the EAHP and 
the SH in the Thessaloniki, Greece. Histopathology 
2006; 48: 481–504.
27. Refaeli Y., Young R., Turner B., Duda J., Field K., Bi-
shop M. The B cell antigen receptor and overexpres-
sion of MYC can cooperate in the genesis of B cell 
lymphomas. PloS Biol. 2008; 6: 152–176.
28. Okubo N., Miyamoto N., Komaki C. Primary mucosa-
-associated lymphoid tissue (MALT) lymphoma of the 
trachea: a case of surgical resection and long term 
survival. Thorax 2005; 60: 82–83.
29. Kang J.Y., Park H.J., Lee K., Lee S.Y., Kim S.J., Park S.H., 
Kim Y.K. Extranodal marginal zone lymphoma occur-
ring along the trachea and central airway. Yonsei Med. 
J. 2008; 5: 860–863. 
30. Lejeune M., Alvaro T. Clinicobiological, prognostic and 
therapeutic implications of the tumor microenvironment 
in follicular lymphoma. Haematologica 2009; 1: 16–21.
